---
title: "Eli Lilly is set to initiate a Phase III study of the GLP-1R/GIPR/GCGR agonist, semaglutide, in a head-to-head comparison."
description: "Recently, Eli Lilly registered a Phase III clinical trial for patients with type 2 diabetes on the clinicaltrials.gov website. The trial aims to evaluate the effectiveness and safety of retatrutide co"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/108040168.md"
published_at: "2024-02-16T07:28:08.000Z"
---

# Eli Lilly is set to initiate a Phase III study of the GLP-1R/GIPR/GCGR agonist, semaglutide, in a head-to-head comparison.

> Recently, Eli Lilly registered a Phase III clinical trial for patients with type 2 diabetes on the clinicaltrials.gov website. The trial aims to evaluate the effectiveness and safety of retatrutide compared to semaglutide in the treatment of poorly controlled blood glucose. The study is expected to start on March 20th this year and last for approximately 26 months, with a projected enrollment of 1250 patients. In addition, Eli Lilly is also accelerating the Phase III TRIUMPH series of studies for retatrutide, which aims to evaluate its safety and effectiveness in the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis.

Zhitong App has learned that recently, the clinicaltrials.gov website showed that Eli Lilly (LLY.US) has registered a randomized, multicenter, open-label Phase III clinical trial for the GLP-1R/GIPR/GCGR triple agonist retatrutide. The trial aims to evaluate the efficacy and safety of retatrutide compared to semaglutide in the treatment of poorly controlled type 2 diabetes patients with or without metformin in combination with a sodium-glucose cotransporter 2 inhibitor (SGLT2i).

It is understood that the study is expected to start on March 20th of this year and will be completed on December 11th, 2026 for the primary research and on March 30th, 2027 for the entire study. The study will last for approximately 26 months and may include up to 24 visits, with an estimated recruitment of 1,250 patients. The primary endpoint is the change in patients' hemoglobin A1c (HbA1c) values from baseline at week 80.

Currently, Eli Lilly (LLY.US) is also accelerating the Phase III TRIUMPH series of studies for retatrutide, which includes four key registration trials. These trials aim to evaluate the safety and efficacy of retatrutide for chronic weight management in obese and overweight patients, obstructive sleep apnea (OSA), and osteoarthritis (OA) of the knee joint.

![Image](https://imageproxy.pbkrs.com/http://img.zhitongcaijing.com/images/contentformat/43a5e62a2bbff77ff36f5c1a8f646f98.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

### Related Stocks

- [GLP.US - Global Partners LP](https://longbridge.com/en/quote/GLP.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 贝森特和沃什的 “导师”，德鲁肯米勒 Q4“精准” 开仓金融股 ETF、标普等权重 ETF 和巴西 ETF | 科技股方面，德鲁肯米勒 Q4 清仓了 Meta，加仓了谷歌与 Sea。德鲁肯米勒与贝森特、沃什的 “师徒” 关系让市场推测，“德鲁肯米勒经济学”——即反赤字、反通胀、反关税——可能通过贝森特和沃什渗透至政策制定中。 | [Link](https://longbridge.com/en/news/276214511.md) |
| 布鲁克代尔老年关怀公司｜8-K：2025 财年 Q4 营收 7.54 亿美元 |  | [Link](https://longbridge.com/en/news/276272851.md) |
| 拜切公司｜10-K：2025 财年营收 10.37 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276487321.md) |
| NOW 公司｜8-K：2025 财年营收 28.2 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276438920.md) |
| 利安德巴塞尔工业｜10-K：2025 财年营收 302 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276482405.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.